Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 155: | Line 155: | ||
[https://www.nature.com/articles/s41541-017-0015-7 by Prakash Srinivasan 22/5/17 npj] | [https://www.nature.com/articles/s41541-017-0015-7 by Prakash Srinivasan 22/5/17 npj] | ||
The Plasmodium falciparum protein, apical membrane antigen 1 forms a complex with another parasite protein, rhoptry neck protein 2, to initiate junction formation with the erythrocyte and is essential for merozoite invasion during the blood stage of infection. Consequently, apical membrane antigen 1 has been a target of vaccine development but vaccination with apical membrane antigen 1 alone in controlled human malaria infections failed to protect and showed limited efficacy in field trials. | The Plasmodium falciparum protein, apical membrane antigen 1 forms a complex with another parasite protein, rhoptry neck protein 2, to initiate junction formation with the erythrocyte and is essential for merozoite invasion during the blood stage of infection. Consequently, apical membrane antigen 1 has been a target of vaccine development but vaccination with apical membrane antigen 1 alone in controlled human malaria infections failed to protect and showed limited efficacy in field trials. | ||
=====Malaria vaccine gives disappointing results===== | |||
[https://www.nature.com/articles/nature.2012.11785 by Declan Butler 9/11/12 nature] | |||
Interim poor results of RTS,S vaccine trial in African children raise question marks over deployment. | |||
